Livdelzi (seladelpar) is a medicine that can treat primary biliary cholangitis (PBC) by reducing the amount of bile in your body. It does this by signaling the body to stop making bile acid.

At the start of the year, there had been no new therapies for rare cholestatic liver disease primary biliary cholangitis (PBC) in the US for almost a decade. With the FDA approval of Gilead's ...

Big drug maker Gilead expects to take a billion-dollar hit this year via drug-pricing provisions in the Inflation Reduction ...

In hepatology, the term overlap syndrome describes variant forms of the major hepatobiliary autoimmune diseases, autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing ...

September is the perfect time to turn up the volume on conversations about Primary Biliary Cholangitis (PBC) and the symptoms people living with it experience, in support of PBC Awareness Month.

I wasn't ill apart from some tiredness.” After being on the organ donor waiting list for four months, Mandy was matched with a unique patient – a donor who had received a liver just three weeks prior ...

These include different types of cholangitis (inflammation of the bile ducts), human immunodeficiency virus (HIV), and primary biliary cirrhosis (a chronic liver disease). In addition to taking ...

Gilead Sciences, Inc.'s strong sales growth in Veklury, Livdelzi, and Trodelvy shows promise for long-term financial success.

Gilead Sciences’ Livdelzi (seladelpar) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with the rare liver disease primary biliary cholangitis (PBC) ...

AIH, autoimmune hepatitis; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; AIC, autoimmune cholangitis; ALT, alanine aminotransferase; AST ...